



18 Nov 2021

Clinical Study Protocol:

APR-633: A phase Ib/II study to investigate the safety and clinical activity of APR-246 in combination with dabrafenib in patients with BRAF V600 mutant unresectable and/or mEtastatic cutaneous MElanoma Resistant to dabrafenib /trametinib combination EMERA trial

EudraCT No: 2017-002577-18

This study was prematurely ended after 2 patients were enrolled due to recruitment challenges, therefore no report was created.

A handwritten signature in black ink, appearing to read "Phillip Gallacher", written over a horizontal line.

Phillip Gallacher
SVP, Clinical Development Operations
Aprea Therapeutics